ClinicalTrials.gg
CompletedNCT03341390Updated Jan 19, 2018

An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants

A Phase 1 interventional study of Aspirin and BMS-986177 in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-19.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2017, 9 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,995 studies in Stroke with a site in United States — 395 open to participants now, 492 under way, 17 of them phase 3. Stroke · United States.

Enrollment
1,104th of 1,621
20 · median 40
Started
2017
with 95 others
Phase 1
126 of 1,995
18 open now
Registered
1,004th of 1,995
by date

Among the 1,995 studies in Stroke with a site in United States, this one is the 1,104th largest by enrollment of the 1,621 interventional ones that give a count, is one of 96 that started in 2017, is one of 126 in phase 1, and was the 1,004th registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

395 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:

390 more — sign in →

All 395 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,995 studies in Stroke with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of taking multiple doses of BMS-986177 when aspirin is taken once-daily. Eligible participants will receive twice-daily doses of BMS-986177 or placebo, with a once-daily dose of aspirin. The safety, tolerability and movement of BMS-986177 into, through and out of the body (pharmacokinetics/PK) will be assessed, as will the effect of BMS-986177 on the PK of aspirin.

03

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • Healthy participants
  • Healthy subjects
  • Strokes
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written consent form.
  • Healthy male and female participants (not of ), determined by no deviation from normal in medical history, physical examination, ECGs () and clinical laboratory determinations.
  • Women participants must have documented proof they are not of childbearing potential.
  • Males sexually active with women of childbearing potential must agree to follow instructions for method(s) of for duration of treatment with BMS-986177, and for a total of 93 days after the last dose of BMS-986177; and must be willing to refrain from sperm donation during this time. Azoospermic males are exempt from contraceptive requirements.
  • Normal renal function at screening (Glomerula Filtration Rate ≥ 80 mL/min/1.73 m2.
  • (BMI) of 18.0 kg/m2 to 32.0 kg/m2 inclusive.

Exclusion criteria

Exclusion Criteria:

  • Women who are of or breastfeeding.
  • Any significant acute or chronic illness.
  • History of gastroesophageal reflux disease, dyspepsia, protracted nausea or chronic diarrhea.
  • History of upper gastrointestinal ulcer disease within 6 months or current symptomatic or recent gastrointestinal disease that could impact absorption of study treatment.
  • Abnormal renal profile and/or hematuria (if male) within 3 months of study start.
  • History or evidence of abnormal bleeding and/or coagulation disorder and/or evidence of coagulopathy, prolonged or unexplained bleeding, or frequent unexplained bruising or thrombus formation, or a history of spontaneous bleeding.
  • Any major surgery within 4 weeks of study treatment administration or planned within 2 weeks after completion of the study.
  • Donation of blood to a blood bank or in a clinical study (except screening or follow-up visit) within 4 weeks of study treatment administration (within 2 weeks for plasma only).
  • Blood transfusion within 3 months of study treatment administration.
  • Use of tobacco- or nicotine-containing products (including, but not limited to cigarettes, pipes, cigars, e-cigarettes, chewing tobacco, nicotine patches, nicotine lozenges or nicotine gum) within 6 months prior to study treatment administration.
  • History of allergy to aspirin or related compounds.

Other protocol-defined inclusion/exclusion criteria could apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Aspirin

    325 mg tablet, once daily for 5 days (Day -5 to -1)

    Drug: Aspirin

  • Experimental
    BMS-986177 plus aspirin

    200 mg BMS-986177 twice daily and 325 mg tablet aspirin once daily (Day 1-7)

    Drug: Aspirin · Drug: BMS-986177

  • Placebo comparator
    Placebo plus aspirin

    200 mg Placebo twice daily and 325 mg tablet aspirin once daily (Day 1-7)

    Drug: Aspirin · Drug: Placebo

Interventions

  • 1 x 325 mg tablet of aspirin administered once daily

    Also known as: Acetylsalicylic Acid

  • 200 mg of BMS-986177 administered twice daily

  • DrugPlacebo

    200 mg of Placebo administered twice daily

06

What researchers measure

Primary outcomes

  1. Number of participants with non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) leading to discontinuation when coadministered BMS-986177 (twice daily) and aspirin (once daily)

    Safety and tolerability of multiple doses of BMS-986177 measured by investigator assessment

    Time frame: Up to 10 days

  2. Number of potential clinically significant changes in electrical activity of the heart in participants coadministered BMS-986177 (twice daily) and aspirin (once daily)

    Measured by electrocardiogram (ECG)

    Time frame: Up to 10 days

  3. Number of participants with vital sign abnormalities.

    Time frame: Up to 10 days

  4. Number of participants with physical examination abnormalities.

    Time frame: Up to 10 days

  5. Number of participants with clinical laboratory abnormalities.

    Time frame: Up to 10 days

07

Study locations

1 site
  • PPD Austin Clinic
    Austin, Texas 78744, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Nov 2017, 0 months.

Of 26 industry-sponsored phase 1 interventional studies under Stroke, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 0 months is below that.

Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2017
First posted
Nov 14, 2017
StartActual
Oct 18, 2017
Primary completionActual
Nov 16, 2017
CompletionActual
Nov 16, 2017
Last update
Jan 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03341390
Responsible party
Sponsor
First posted
Nov 14, 2017
Start date
Oct 18, 2017
Primary completion
Nov 16, 2017
Completion
Nov 16, 2017
Last update
Jan 19, 2018

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion